AstraZeneca Sponsored Study Conflicts with SAVOR Review by the FDA, which Indicated Potential 27% Increased Risk of Hospitalization from Heart Failure Among Onglyza Users
Just a few months after the U.S. Food and Drug Administration (FDA) called for stronger warnings regarding the alleged risk of heart failure from Onglyza treatment, the maker of the Type 2 diabetes drug has presented new research that appears to question that risk. If you took the widely-used diabetes medication, Onglyza, and you have since suffered heart failure, hospitalization, or another serious side effect, consult an experienced Onglyza lawyer today for legal help. You may have grounds to file an Onglyza lawsuit against AstraZeneca, in order to seek fair and timely reimbursement for your injuries, medical expenses, and pain and suffering.
FDA Warns Onglyza Diabetes Drug May Increase Risk of Patient Death
AstraZeneca’s blockbuster diabetes drug Onglyza may be linked to an increased risk of death for some patients, according to a preliminary review of clinical trial data by the U.S. Food and Drug Administration (FDA). The FDA report was published on the agency’s website ahead of a scheduled FDA advisory panel meeting in April 2015, to discuss the potential for Onglyza and a similar diabetes drug to cause life-threatening cardiovascular side effects in users. If you took Onglyza in the past, and you have since suffered heart failure or another major complication, consult an experienced Onglyza injury lawyer today to explore your possible compensation options.
Possible Side Effects of Onglyza.
Latest News on Link Between DPP-4 Inhibitor Drugs Onglyza and Januvia and Pancreatic Cancer
Potential Link Between DPP-4 Inhibitor Drugs and Pancreatic Cancer Remains Unknown
The risk of pancreatitis and pancreatic cancer from diabetes medications is not a new concern, but new information suggests that short-term use of the drugs does not increase the risk of pancreatic cancer, as was previously reported in earlier studies. Still, there is limited research involving long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitor medications for Type 2 diabetes, and as new information comes to light about the potential for Invokana and other SGLT-2 inhibitor diabetes drugs to cause serious side effects like ketoacidosis, diabetes patients should be aware of the injuries they may be exposing themselves to by taking certain prescription medications. If you took Onglyza or another DPP-4 inhibitor in the past, and you have since been diagnosed with pancreatitis or pancreatic cancer, contact a skilled product liability lawyer today for legal help.
Latest News on Popular Diabetes Drug Invokana, Diabetic Ketoacidosis, Kidney Failure, Death
Popular Diabetes Drugs Linked to Reports of Diabetic Ketoacidosis, Death
A popular class of Type 2 diabetes medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors have been tied to reports of severe and potentially life-threatening side effects in users, including heart attack, kidney failure and diabetic ketoacidosis (DKA), a serious medical condition that can lead to diabetic coma and death. Some of the most popular SGLT2 drugs on the market today include Invokana (canagliflozin), Invokamet (canagliflozin/metformin), Glyxambi (empagliflozin/linagliptin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin/metformin) and Jardiance (empagliflozin). If you took one or more of these diabetes drugs, and you have since suffered a devastating side effect like kidney failure or diabetic ketoacidosis, consult an experienced product liability lawyer today for legal help.